In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Immunomedics grants UCB rights to epratuzumab; rights returned

Executive Summary

Immunomedics (MAbs for cancer and autoimmune diseases) has granted UCB exclusive worldwide rights to develop, market, and sell the humanized monoclonal antibody epratuzumab for all autoimmune disease indications. The compound targets an antigen called CD22 and has already shown potential for systemic lupus erythematosus (SLE) and Sjögren's syndrome.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies